Pregabalin Capsule
Product Images NDC 70518-3636

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-3636). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin is a medication available in the form of capsules with a strength of 50mg. A quantity of 90 capsules is provided and it's a prescription-only drug. The medication is sourced from Ascend Labs, LLC located in Montvale, NJ 07645. The lot number is not available. Patients are advised to store the medication at a temperature between 20-25°C and keep it away from children. Directions for use are present in the package insert. The drug is repackaged by RemedyRepack Inc. located in Indiana, PA 15701.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

This appears to be a medical equation for estimating creatinine clearance (CLCr) based on age, weight, and serum creatinine level (measured in mg/dL). The equation involves multiplying 140 by the patient's weight and dividing by their serum creatinine level, adjusted for age. The note about a CLCr value greater than 0.85 for female patients suggests this equation may be used in the context of renal function assessment.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

This appears to be a table containing data from Study E1 and Study E3, with different treatment groups and percentages. The study involves testing the effectiveness of various dosages of a drug (ranging from 50mg/day to 600mg/day) compared to a placebo. The table seems to show that some dosages of the drug were statistically significant compared to the placebo, but without more context it is difficult to draw conclusions about the study's findings.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

The text provides information on the percentage of patients who improved in pain from baseline after being prescribed Pregabalin in either 200mg or 100mg doses three times a day, compared to a placebo. The exact percentage is not available due to errors in .*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

The text is a chart showing the percentage of patients who improved with different doses of Pregabalin for pain relief. It also includes the percentage of improvement in pain from the baseline for each dose.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.